EOHCdelisted

Edison Oncology Holding Corp

Healthcare·Oncology·Phase 3
Oncology

Edison Oncology Holding Corp (EOHC): 1 pipeline candidate · 1 clinical trial. Updated within the last hour.

5.9/10

BioSniper Score

2-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial HealthN/A

N/A

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Edison Oncology Holding Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Pipeline (1 candidate)

DrugPhase
lomustinePhase 3
1 clinical trial

Frequently asked questions

How many drug candidates are in Edison Oncology Holding Corp's pipeline?

Edison Oncology Holding Corp (EOHC) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.

What is Edison Oncology Holding Corp's lead drug candidate?

Edison Oncology Holding Corp's most advanced tracked candidate is lomustine (Phase 3) for Glioblastoma.

Get the full picture on Edison Oncology Holding Corp

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar